0002-7140 NDC - REOPRO (ABCIXIMAB)

Drug Information

Product NDC: 0002-7140

Proprietary Name: REOPRO

Non Proprietary Name: abciximab

Active Ingredient(s):
  • 2 mg/mL ABCIXIMAB


Administration Route(s): INTRAVENOUS

Dosage Form(s): INJECTION, SOLUTION

Labeler Information

Labeler Name: Eli Lilly and Company
Product Type: HUMAN PRESCRIPTION DRUG
FDA Application Number: BLA103575
Marketing Category: BLA
Start Marketing Date:12/16/1993
End Marketing Date:1/31/2019

Package Information

No. Package Code Package Description Billing Unit
10002-7140-015 mL in 1 VIAL, SINGLE-USE (0002-7140-01)ML

NDC Record

Field Name Field Value Definition
PRODUCT NDC0002-7140The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
PRODUCT TYPE NAMEHUMAN PRESCRIPTION DRUGIndicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
PROPRIETARY NAMEREOPROThe proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
NON PROPRIETARY NAMEabciximabThe non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
DOSAGE FORM NAMEINJECTION, SOLUTIONThe translation of the dosage form Code submitted by the firm.
ROUTE NAMEINTRAVENOUSThe translation of the route code submitted by the firm, indicating route of administration.
START MARKETING DATE12/16/1993This is the date that the labeler indicates was the start of its marketing of the drug product.
END MARKETING DATE1/31/2019This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
MARKETING CATEGORY NAMEBLAProduct types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
APPLICATION NUMBERBLA103575This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
LABELER NAMEEli Lilly and CompanyName of Company corresponding to the labeler code segment of the Product NDC.
SUBSTANCE NAMEABCIXIMABThis is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
ACTIVE NUMERATOR STRENGTH2 
ACTIVE INGRED UNITmg/mL 

Download Record

Download this NDC record in Text format: Export

Download this NDC record in Excel (CSV) format: Export

Download this NDC record in XML format: Export

This page was last updated on: 9/5/2018